Drug intelligence / Profile preview

ZB014

Development stage: Preclinical
Lead developer: Zenas BioPharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

ZB014 is a half-life extended monoclonal antibody that dual-targets B-lymphocyte antigen CD19 and the inhibitory receptor FcγRIIb. Developed by Zenas BioPharma, the therapeutic is designed to treat autoimmune diseases by suppressing B-cell activation. By co-engaging CD19 and FcγRIIb, ZB014 leverages the natural inhibitory signaling of the FcγRIIb receptor to downregulate B-cell receptor-mediated signaling. The molecule features an engineered Fc domain to extend its circulating half-life, potentially allowing for less frequent dosing compared to first-generation antibodies. As of March 2026, ZB014 is in preclinical development.

Targets

CD19 (B lymphocyte antigen CD19)FCGR2B (Fc gamma receptor IIB)

Beyond the preview

Go deeper on ZB014.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZB014.

Explore the full profile